PoozeSCAF discovery solutions

PozeSCAF, formerly known as Immunocure, is an AI-powered contract research organization (CRO) specializing in small molecule and biologics drug discovery. The company utilizes its proprietary AI platform, AxDrug, to enable end-to-end discovery processes, ranging from target identification through to IND-enabling studies. Their technical infrastructure combines computational chemistry—including structure-based design, FEP-based ranking, and in silico ADMET prediction—with medicinal chemistry and synthesis services. The company differentiates its approach by integrating these computational capabilities with experimental validation to optimize hit identification, lead generation, and lead optimization for diverse therapeutic areas, including oncology and the development of PROTACs and molecular glues.

By providing integrated, interdisciplinary services, PozeSCAF helps biopharma companies reduce iteration cycles and accelerate research timelines. They support clients through various stages of the drug discovery pipeline, from designing custom chemical libraries to executing synthetic routes. The company's expertise and platform are leveraged by multinational collaborators and academic institutions to improve the precision of candidate prioritization and enhance the success rates of moving projects into clinical development. Their operations, which interface computational design with in vitro biology, are designed to assist organizations in reaching discovery milestones more efficiently and reliably.